Meeting slides
Suggested Readings

From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

Defronzo RA. Diabetes. 2009;58(4):773-795.

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant M, Nauck MA, Shaginian R, et al. Diabetes Care. 2014;37(10):2763-2773.

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

Goring S, Hawkins N, Wygant G, et al. Diabetes Obes Metab. 2014;16(5):433-442.

Glycemic variability and diabetes complications: Does it matter? Of course it does!

Hirsch IB. Diabetes Care. 2015;38(8):1610-1614.

Minimizing hypoglycemia in diabetes

International Hypoglycemia Study Group. Diabetes Care. 2015;38(8):1583-1591.

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care. 2015;38(1):140-149.

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Kawalec P, Mikrut A, Łopuch S. Diabetes Metab Res Rev. 2014;30(4):269-283.

Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: rationale and evidence for early initiation.

Milligan S. J Diabetes Complications. 2016 Mar 15 [Epub ahead of print].

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Diabetes Obes Metab. 2014;16(5):410-417.

GLP-1 receptor agonists: Practical considerations for clinical practice.

Triplitt C, Solis-Herrera C. Diabetes Educ. 2015;41(1 Suppl):32S-46S.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.

Linked Resources


Standards of medical care in diabetes—2016.

The ADA’s Standards of Care provide clinicians, patients, researchers, payers, and other interested individuals with the components of good diabetes management, general treatment goals, and tools to evaluate the quality of care. Importantly, these recommendations should be adjusted based on individual preferences, comorbidities, and other patient-related factors.
American Diabetes Association.  Diabetes Care. 2015;38(suppl 1):S1-S94.

AACE/ACE comprehensive diabetes management algorithm 2016.

This algorithm from the AACE addresses evaluating the whole patient, potential risks and complications, and evidence-based treatment approaches for diabetes. The document contains sections on obesity, prediabetes, hyperglycemia therapy (lifestyle modifications, pharmacotherapy, and insulin), hypertension management, hyperlipidemia treatment, and other risk-reduction strategies.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2015;21(4):438-447.

Patient Resources

Diabetes HealthSense 

Provides easy access to resources to help patients live well and meet their goals—whether they have diabetes or are at risk for the disease.

Decision Aids for T2DM

To facilitate shared decision making, these examples of medication choice decision aids from the Mayo Clinic are organized into 7 issues that may be of interest to patients with T2DM. A video demonstrating the use of these cards can be found at:

Related activities
1.00 CME

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

Faculty: John E. Anderson, MD; Alan J. Garber, MD, PhD, FACE; Julio Rosenstock, MD
Release: 01/30/2017
Expiration: 01/30/2018